Sarcio

Sarcio is a private, pre-clinical-stage biotech developing a novel exosome-based regenerative therapy for osteoarthritis. Its core technology platform utilizes iPSC-derived cartilage to produce exosomes with targeted regenerative signals, offering a potentially disease-modifying and scalable alternative to current palliative treatments. The company is led by a seasoned team with expertise in stem cell biology, orthopedics, and biopharmaceutical commercialization, positioning it to address a massive unmet medical need in a large and growing market.

Proprietary platform using induced pluripotent stem cells (iPSCs) differentiated into cartilage tissue to produce tissue-specific exosomes. These exosomes are engineered to carry regenerative signals to promote healing and repair in damaged joints.

Sarcio competes in the active but unproven field of disease-modifying osteoarthritis therapies, facing companies developing cell-based therapies (e.g., mesenchymal stem cell injections), gene therapies, and other novel biologics. Its differentiation lies in its specific iPSC-derived cartilage exosome approach, aiming for targeted signaling versus cell engraftment.